Jing Yuan

Dr. Jing Yuan

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2021 in Frontiers in Psychiatry
Verified
Journal Article
Open access
CKChuanyuan Kang
Chuanyuan Kang
SSShufang Sun
Shufang Sun
ZYZhuangqing Yang
Zhuangqing Yang
XFXinxin Fan
Xinxin Fan
JYJing Yuan
Jing Yuan
JYJianzhong Yang
Jianzhong Yang
Objective: To examine the efficacy and the role of engagement of an internet-based Mindfulness-based Stress Reduction (iMBSR) for survivors of breast cancer (BC) during the COVID-19 period from January to March in 2020 in China.Methods: 48 survivors of BC were divided into the absentees group and the iMBSR groups according to their attending to the standardized, group-based, 8-week iMBSR. Based on practice time, survivors of BC in the iMBSR were categorized into three subgroups: group 1 (60 min/day). In addition, participants were classified as partial attendees (30 min daily practice for most optimal symptoms reduction.Trial Registration: Registration number is [ChiCTR2100044309].

30 April 2020 in Psychiatry Research
Verified
Journal Article
Open access
PDF file
CKChuanyuan Kang
Chuanyuan Kang
FMFu Meng
Fu Meng
QFQiang Feng
Qiang Feng
JYJing Yuan
Jing Yuan
LLLiang Liu
Liang Liu
JYJianzhong Yang
Jianzhong Yang

17 August 2022 in Immunity, Inflammation and Disease
Verified
Journal Article
Open access
JYJing Yuan
Jing Yuan
HRHan‐Yun Ren
Han‐Yun Ren
Background: The C–C chemokine receptor 5 (CCR5) is mainly expressed in a variety of immune cells. It interacts with multiple chemokine ligands that mediate the trafficking and recruitment of effector cells toward sites of inflammation. CCR5 not only plays a critical role in cell growth, activation, differentiation, adhesion, and migration but also participates in the development of acute graft‐versus‐host disease (GVHD) after allogeneic hematopoietic cell transplantation.Methods: This is a literature review article. The research design method is an evidence‐based rapid review. The present discourse aim is first to scrutinize and assess the available literature on CCR5 and acute GVHD. Standard literature and database searches were implemented, gathered relevant material, and extracted information was then assessed.Results: CCR5 is a marker of GVHD effector cells, and CCR5 expression is elevated when acute GVHD occurs. CCR5 blockade with maraviroc in clinical trials results in a low incidence of acute GVHD. The immune mechanism includes that CCR5 blockade inhibits donor T cell migration and recruitment toward target organs, reduces the absolute numbers of donor T cells, is capable of slightly suppressing dendritic cell maturation, and reduces the percentage of Th1 and Th17 subsets. CCR5 blockade also inhibits internalization and activation of chemokines, inhibits proliferation and chemotaxis of T cells, and decreases the production of TNF‐α and IFN‐γ. In addition, there may be a form of crosstalk between CCR5 and CCR2. Inconsistently, infusion of CCR5−/− Tregs into lethally irradiated mice significantly increased the infiltration of CD4+ and CD8+ T cells into the liver, resulting in earlier and more severe GVHD.Conclusion: This review indicates that CCR5 plays an important role in pathogenesis and development of acute GVHD. Elucidating its role in different immune cells will aid the development of targeted therapeutic treatments.

12 June 2019 in Molecular and Clinical Oncology
Verified
Journal Article
Open access
PDF file
RGRuo‑Lan Gu
Ruo‑Lan Gu
MXMing Xiang
Ming Xiang
JSJing Suo
Jing Suo
JYJing Yuan
Jing Yuan
This case report describes a case of an unusual initial presentation of acute lymphoblastic leukemia in a previously healthy 15‑year‑old boy. He initially presented with a 6‑day history of tiredness, decreased oral intake, nausea, vomiting, and jaundice (yellow sclera and dark urine) with evidence of acute hepatic failure, presenting as an increase in alanine aminotransferase (ALT)/aspartate aminotransferase (AST)/total bilirubin and a decrease in prothrombin activity. A complete serological evaluation for liver disease was negative. The levels of serum AST and ALT declined following hepatoprotective treatment. Bone marrow biopsy was diagnostic, revealing 68.15% blasts with markers consistent with acute B‑cell lymphoblastic leukemia. This case report emphasizes that acute hepatic failure may be the initial presentation of ALL in an adolescent.

20 March 2023 in Stem Cell Research & Therapy
Verified
Journal Article
Open access
PDF file
JYJing Yuan
Jing Yuan
FWFuxu Wang
Fuxu Wang
HRHanyun Ren
Hanyun Ren
A 24-year-old man with central nervous system (CNS) involvement of T-cell lineage acute lymphoblastic leukemia received sibling allogeneic stem cell transplantation (allo-SCT). He developed isolated CNS relapse early post-SCT, while high-dose systemic chemotherapy, intrathecal (IT) triple infusion and IT donor lymphocytes infusion (DLI) all demonstrated effectiveness. We performed IT umbilical cord blood-derived CAR-NK (target CD7) cells infusion, which was not previously reported. After infusion, detection of cytokines revealed that interferon-γ, interleukin-6 and interleukin-8 increased in CSF. He developed high fever, headache, nausea, vomiting and a spinal cord transection with incontinence in a short time, whereas the ptosis and blurred vision improved completely. The bone marrow remained encouragingly complete remission and complete donor chimerism over 9 months after IT CAR-NK cells infusion. In conclusion, IT CAR-NK cells infusion is a potentially feasible and effective option for patients with CNS relapse, with limited neurological toxicity.

1 September 2023 in Journal of Inflammation Research
Verified
Journal Article
Open access
PDF file
JYJing Yuan
Jing Yuan
XLXuan Liu
Xuan Liu
ZWZhenzhen Wang
Zhenzhen Wang
LLLiyuan Li
Liyuan Li
FWFuxu Wang
Fuxu Wang
Concurrent polycythemia vera with newly diagnosed multiple myeloma is extremely rare. We described a 70-year-old woman with concurrent polycythemia vera and newly diagnosed multiple myeloma. Genetic testing confirmed the JAK2 V617F mutation for the first time, while determination of serum erythropoietin decreased. A retrospective review of our patient’s case was conducted thereafter, and related literature was systemically reviewed. We totally identified eight cases with concurrent polycythemia vera with newly diagnosed multiple myeloma, which were further analyzed and compared. The present case is the first patient of newly diagnosed multiple myeloma with diagnosis of polycythemia vera confirmed by positive JAK2 V617F mutation. Abnormal erythremia, hepatosplenomegaly and thrombosis history suggested comorbidity of polycythemia vera with newly diagnosed multiple myeloma. The bortezomib-based chemotherapy regimen seemed to be effective on controlling the proliferation of erythrocyte. Whereas the pathogenesis of these two entities remains to be further investigated.